Clinical Trial Update: Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) [Phase 2]

View source ↗

Summary

Phase 2 COMET trial evaluating Tumor Treating Fields at 150 kHz in non-small cell lung cancer patients with 1-5 brain metastases after standard local therapy; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Tumor Treating Fields (TTFields)

Snippet

Sponsor: NovoCure Ltd. | Conditions: 1-5 Brain Metastases From Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN